PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-6.90
Negative P/E while Drug Manufacturers - Specialty & Generic median is 0.00. Seth Klarman would scrutinize path to profitability versus peers.
20.74
P/S exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 11.71. Jim Chanos would check for potential multiple compression risks.
1.76
P/B 50-90% of Drug Manufacturers - Specialty & Generic median of 1.96. Mohnish Pabrai would examine if this discount presents opportunity.
-196.19
Negative FCF while Drug Manufacturers - Specialty & Generic median P/FCF is -8.83. Seth Klarman would investigate cash flow improvement potential.
1154.27
P/OCF of 1154.27 versus zero operating cash flow in Drug Manufacturers - Specialty & Generic. Walter Schloss would verify operational quality.
1.76
Fair value ratio 50-90% of Drug Manufacturers - Specialty & Generic median of 1.96. Mohnish Pabrai would examine if this gap presents opportunity.
-3.62%
Negative earnings while Drug Manufacturers - Specialty & Generic median yield is 0.00%. Seth Klarman would investigate path to profitability.
-0.51%
Negative FCF while Drug Manufacturers - Specialty & Generic median yield is -0.14%. Seth Klarman would investigate cash flow improvement potential.